Fc␥RIIA is a candidate gene involved in the predisposition to systemic lupus erythematosus (SLE
Introduction
Fc gamma receptors (Fc␥R) are members of the immunoglobulin superfamily, which bind monomeric IgG and IgG-containing immune complexes and play important roles in inflammation and immunomodulation. In humans, the Fc␥R genes are clustered on the long arm of chromosome 1 (1q21-23). Extensive structural diversity among FcgR family members leads to differences in binding capacity, distinct signal transduction pathways, and cell-type specific expression patterns. 1 Structural defects in Fc␥RIIa and/or alterations in Fc␥RIIa expression could play a pivotal role in the predisposition to and development of autoimmunity. Alterations in the extracellular domain of Fc␥RIIa influence the ability of this receptor to bind human IgG2 and profoundly affect phagocyte biologic activity. [2] [3] [4] Linkage and association studies have suggested the low IgG2 binding allele of Fc␥RIIa, R131, is a genetic risk factor in systemic lupus erythematosus (SLE). 5, 6 However, comparison of Fc␥RIIa function in SLE patients and disease-free controls with identical Fc␥RIIa genotypes showed that patients had lower phagocytic capacity than disease-free individuals. [7] [8] [9] Therefore the presence of low binding alleles alone does not account for the Fc␥R defects described in SLE patients. A systematic decline in the expression levels of Fc␥RIIa may contribute to the impaired function of mononuclear phagocyte system in SLE. As polymorphisms in the promoter of the human Fc␥RIIA genes may alter the constitutive and/or induced expression of this receptor, we considered the possibility that nucleotide polymorphisms in the Fc␥RIIA promoter that cause alterations in receptor expression, might be present in SLE patients.
Results and discussion

Sequence analysis of the human Fc␥RIIA promoter and 5ЈUTR
The sequence of the human Fc␥RIIA promoter has been reported (GenBank accession number X68090). Our initial sequencing data of this region in six normal Caucasian control subjects showed numerous differences compared with the published Fc␥RIIA 5Ј sequence. As illustrated in Figure 1 , these differences included 34 single base pair substitutions, three single base pair deletions and four single base pair insertions. The initial sequences were identical among all six donors and evident in sequences in both directions, suggesting that differences between the published GenBank sequence and our data are unlikely to be the result of polymerase chain reaction (PCR)-induced mutations. To address the possibility that differences in the ethnicity of the donors could explain sequence differences seen in the GenBank sequence of the Fc␥RIIA promoter, we sequenced the 2.0 kb of the Fc␥RIIA 5Ј region from additional five African American, two Chinese and seven Hispanic normal donors. We identified two novel single nucleotide polymor- 
Sequence analysis and SNP distribution in the Fc␥RIIA promoter of SLE patients
To determine the presence of sequence differences in the promoter region of the human Fc␥RIIA in SLE patients compared with normal controls, we have sequenced this region in 43 SLE patients chosen from our University of Southern California (USC) collection of SLE. Of these 43 patients, 13 were Caucasian, 15 Hispanic, 10 African American and five were of Chinese origin. Forty-one of the SLE patients were females and two were males; 24 had biopsy documented kidney disease; three had CNS lupus. They were between the ages of 19 and 47; with a mean time from diagnosis of 7.2 years. The nt1082 T/G SNP was identified in two SLE patients of Hispanic origin (one with and the other without kidney disease) while the nt295 T/G SNP was found in only one African American SLE patient. Otherwise no other differences in the sequence of these 2000 bp were identified in these SLE patients compared to the normal controls.
Interestingly, in several lupus prone mouse strains a major polymorphism is present in the promoter of the Fc␥RIIB gene and consists of a 13-bp deletion interrupting two putative transcription factor binding sites, an AP4 site and a partially overlapping S box. 10 The Genbank sequence of the human Fc␥RIIA promoter shows two putative AP4 binding sites (−181 to −173 and −1670 to −1662). However, we found an insertion and two substitutions within these sequences. The corrected sequence suggests the loss of AP4 consensus motives at these sites ( Figure 2 ).
An alternative approach to identify patients with possible alterations in the Fc␥RIIA promoter is to study those with evidence of Fc␥RIIa dysfunction. Because there are no reagents to specifically measure Fc␥RIIa expression (as distinct from Fc␥RIIb) we identified patients with low and high Fc␥RIIa-mediated phagocytic function. SLE patients (n = 20) were stratified according to the capacity of blood monocytes to internalize the Fc␥RIIa-targeted particles, which were not sensitive to Fc␥RIIa-R131/H131 allelic variation. 5, 7 The phagocytic capacity for the SLE patients was 85 ± 11 particles/100 monocytes compared with 168 ± 15 for disease-free controls. The 2.0 Kb Fc␥RIIA 5ЈUTR was sequenced from five SLE patients with high (greater than 2 s.d. above the mean) and five SLE patients with low phagocytic (greater than 2 s.d. below the mean) capacity. There were three females and two males among the low phagocytic patients; three were Caucasian, one Hispanic and one Asian; four patients met ACR criteria for renal disease. The five high phagocytic SLE patients were all females; two were Caucasian, two African American and one Hispanic; three patients met American College of Rheumatology (ACR) criteria for renal disease. We PCR-amplified a 2.0-kb DNA fragment from the Fc␥RIIA 5Ј region of these patients and sequenced it in both directions. The sequence analysis was identical in all SLE patients and no SNPs were identified in any of the 10 patients whether they had low phagocytosis or high phagocytosis. We conclude from these experiments that internalization mediated by Fc␥RIIa is decreased in SLE patients in the absence of Fc␥RIIA promoter mutations.
With this study we have elucidated the correct sequence of 2.0 kb of the promoter of the human Fc␥RIIA gene. This will facilitate further analysis of immunomodulatory stimuli involved in Fc␥RIIA transcriptional regulation, and provide new insights into the mechanism(s) underlying Fc␥RIIA expression and function at sites of inflammation.
Materials and methods
Normal donor and patient population
Patients were recruited from the USC School of Medicine clinics that were confirmed to have met the ACR criteria for SLE. Disease-free controls were recruited from volunteers within this medical center and written consent was obtained from all subjects. For the purpose of this study normal controls were defined as subjects who did not have SLE or any other autoimmune disease and whose family lacked any autoimmune disease history per interview of the subjects. In addition each normal control was ANA negative. The Institutional Review Boards approved the study.
A second group of subjects with well-characterized Fc␥RIIa phagocytic function were identified from Hospital for Special Surgery in New York. Fc␥RIIa-mediated phagocytic function was quantitated using erythrocytes coated with mAb reactive with Fc␥RIIa, as previously described. 11 Twenty SLE patients meeting ACR criteria and ethnically similar disease-free controls were studied.
PCR amplification and sequence analysis
The 5Ј flanking region of the Fc␥RIIA was amplified from −2000 to +27 using oligonucleotide primers from the NCBI GenBank sequence accession number X68090. The following primers were used: 5Ј- GTTGGACTGAGGTG-3Ј  5Ј-TAGTCCTAGCCATGATCAC-3Ј  5Ј-GGCATGATAACTAGCAACCAC-3Ј  5Ј-GTTGCCCAGGATGGTCTCG-3Ј  5Ј-TGCTCCGCATGGGTAGTTCC-3Ј  5Ј-TCCGGGTTCACGCCATTCTC-3Ј  5Ј-AGGAGAACAGTAACCCTCCC-3Ј  5Ј-CTATGGAGACCCAAATGTCTCAG-3Ј PCR was done in a total volume of 100 l containing 10 ng of genomic DNA, 50 mM KCI, 10 Mm Tris-HCI, ph 8.3, 1.5 mM MgCI, 250 M each dATP, dCTP, dGTP, dTTP, 1 M each primer and 5 units Promega's Taq.DNA Polymerase. PCR undergone in PE/ABI's 9600 machine with program: 94°C/4 min for denaturing, followed by extension 94°C/1 min, 58°C/1 min, and 72°C/2 min for 30 cycles, post extension 72°C/10 min, soaked at 4°C for overnight. PCR products were purified from 1% of low melting gel with phenol and chloroform.
The purified PCR products (50 ng) were used as sequencing templates. Sequencing reaction was prepared with PE/ABI's Big Dye terminator Cycle Sequencing Ready Reaction kit (catalogue no. 4303152). Sequencing products was purified through PHARMIGEN/ AMERSHAM's G-50 columns (catalogue no. 275330). The purified sequencing products were run with PE/ABI's 3100 Detection System and analysed with Sequencing Analysis Software 3.7. The primers used for sequencing were the same we used for PCR.
